by The global alpha emitter market size was valued at USD 581.6 million in 2023 and is expected to reach around USD 1,488.02 million by 2033, notable at a CAGR of 9.90% from 2024 to 2033.
Key Takeaways
- North America contributed more than 44% of market share in 2023.
- Asia-Pacific is estimated to expand at the fastest CAGR between 2024 and 2033.
- By type of radionuclide, the actinium (Ac-225) segment has held the largest market share of 38% in 2023.
- By type of radionuclide, the radium (Ra-223) segment is anticipated to grow at a remarkable CAGR of 10.16% between 2024 and 2033.
- By application, the bone metastases segment generated over 36% of the market share in 2023.
- By application, the prostate cancer segment is expected to expand at the fastest CAGR over the projected period.
- By source, the natural sources segment generated over 54% of the market share in 2023.
- By source, the artificially produced sources segment is expected to expand at the fastest CAGR over the projected period.
The Alpha Emitter market is experiencing robust growth, driven by several key factors that contribute to its expansion and prominence in various industries. These growth factors are instrumental in shaping the market landscape and influencing the demand for alpha emitters across diverse applications.
Get a Sample: https://www.precedenceresearch.com/sample/3690
Growth Factors
One of the primary drivers fueling the growth of the Alpha Emitter market is the increasing adoption of alpha emitters in medical applications, particularly in cancer treatment. The unique properties of alpha emitters make them effective in targeted cancer therapies, leading to a rising demand within the healthcare sector. Additionally, advancements in nuclear medicine and radiopharmaceutical research further contribute to the market’s positive trajectory.
Alpha Emitter Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 9.90% |
| Global Market Size in 2023 | USD 581.6 Million |
| Global Market Size by 2033 | USD 1,488.02 Million |
| U.S. Market Size in 2023 | USD 179.13 Million |
| U.S. Market Size by 2033 | USD 466.72 Million |
| Base Year | 2023 |
| Forecast Period | 2024 To 2033 |
| Segments Covered | By Type of Radionuclide, By Application, By Source |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Metaverse in E-commerce Market Size to Grow USD 936.28 Bn By 2033
Alpha Emitter Market Dynamics
Drivers
The market is propelled by technological advancements and innovations in alpha emitter production and application. Ongoing research and development efforts are leading to the creation of novel alpha emitters with enhanced properties, widening their scope in various industrial applications. The expanding use of alpha emitters in oil and gas exploration and certain manufacturing processes is another significant driver fostering market growth.
Restraints
Despite the promising growth, the Alpha Emitter market faces certain restraints that need consideration. Regulatory challenges and concerns regarding the safe handling and disposal of alpha-emitting materials pose obstacles to market expansion. Stricter regulations and compliance standards impact the market dynamics, requiring industry players to invest in stringent safety measures.
Opportunities
Amid challenges, the market presents lucrative opportunities driven by the increasing awareness of alpha emitters’ potential benefits. Opportunities lie in educating end-users about the advantages of alpha emitters in specific applications, fostering a greater understanding and acceptance. Additionally, expanding research and development activities can unlock new opportunities for alpha emitter applications in emerging sectors.
Region Snapshot
Geographically, the Alpha Emitter market exhibits a varied landscape with regional nuances influencing market dynamics. North America holds a significant share, driven by a strong presence of key market players and substantial investments in healthcare and research. The Asia-Pacific region is emerging as a key player, with growing industrialization and increasing healthcare expenditures contributing to market growth. Europe, too, is a noteworthy market player with a focus on sustainable practices in nuclear technologies.
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Recent Developments
- In November 2022, NorthStar Medical Radioisotopes, a pharmaceutical company, and IBA Worldwide, a medical technology firm, unveiled a new agreement. NorthStar will acquire its third Rhodotron TT300 HE electron beam accelerator from IBA. This accelerator plays a crucial role in producing no-carrier added actinium-225 (Ac225), a vital therapeutic radioisotope facing limited supply and lacking commercial-scale production technology.
- In January 2022, biotechnology companies RadioMedix and Orano Med announced the commencement of a Phase II clinical trial for AlphaMedix. The trial, initiated on December 21, 2021, assesses the safety and efficacy of 212Pb-DOTAMTATE (AlphaMedix) in Peptide Receptor Radionuclide Therapy (PRRT) for patients with somatostatin receptor-expressing neuroendocrine tumors (NET) who are new to treatment.
- In June 2022, medical technology company Alpha Tau Medical Ltd. received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) application. This green light allows the initiation of a multi-center pivotal study using Alpha DaRT for the treatment of recurrent cutaneous Squamous Cell Carcinoma (SCC).
Alpha Emitter Market Companies
- Alpha Tau Medical Ltd.
- NorthStar Medical Radioisotopes
- IBA Worldwide
- RadioMedix
- Orano Med
- Bayer AG
- Novartis International AG
- Actinium Pharmaceuticals, Inc.
- Fusion Pharmaceuticals Inc.
- Eckert & Ziegler
- Telix Pharmaceuticals Limited
- Curium Pharma
- AAA (Advanced Accelerator Applications)
- Isotopen Technologien München AG (ITM)
- Nordion (Canada) Inc.
Segments Covered in the Report
By Type of Radionuclide
- Radium (Ra-223)
- Actinium (Ac-225)
- Lead (Pb-212)
- Astatine-211
- Bismuth-213
- Others
By Application
- Bone Metastases
- Prostate Cancer
- Neuroendocrine Tumors
- Ovarian Cancer
- Others
By Source
- Natural Sources (Uranium-238, Radium-226)
- Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Alpha Emitter Market
5.1. COVID-19 Landscape: Alpha Emitter Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Alpha Emitter Market, By Type of Radionuclide
8.1. Alpha Emitter Market, by Type of Radionuclide, 2024-2033
8.1.1 Radium (Ra-223)
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Actinium (Ac-225)
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Lead (Pb-212)
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Astatine-211
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Bismuth-213
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Alpha Emitter Market, By Application
9.1. Alpha Emitter Market, by Application, 2024-2033
9.1.1. Bone Metastases
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Prostate Cancer
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Neuroendocrine Tumors
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Ovarian Cancer
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Alpha Emitter Market, By Source
10.1. Alpha Emitter Market, by Source, 2024-2033
10.1.1. Natural Sources (Uranium-238, Radium-226)
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Alpha Emitter Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.3. Market Revenue and Forecast, by Source (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Source (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Source (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.3. Market Revenue and Forecast, by Source (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Source (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Source (2021-2033)
Chapter 12. Company Profiles
12.1. Alpha Tau Medical Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. NorthStar Medical Radioisotopes
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. IBA Worldwide
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. RadioMedix
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Orano Med
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bayer AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novartis International AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Actinium Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Fusion Pharmaceuticals Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Eckert & Ziegler
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
